Twist Bioscience Beat on Revenue, Lost on Trust: Can Q3 Be a Real Turn?

Revenue beat was not enough because profitability still lagged

Twist's quarter sent one clear message: investors want proof on earnings, not just another demand story. The company delivered record revenue of $118.4 million and raised fiscal 2026 guidance to $456 million-$457 million, yet the stock still fell 7.7% in premarket trading. That reaction suggests the market is focused less on top-line growth and more on whether Twist can finally convert better margins into real profit.

The reason for that skepticism is straightforward. Adjusted earnings of $0.56 a share represented a wider loss than expected, even as gross margin improved. When a company beats on revenue and still gets sold, the key question becomes whether the margin improvement is durable enough to support operating leverage, not just whether demand is holding up.

Why Q4 matters more than Q3

That is why the final quarter of the fiscal year matters so much. Twist has reiterated Q4 FY26 Adj EBITDA breakeven. If it hits that target, the stock can start to be priced as an operating turn. If it misses again, investors will have less reason to look past another quarter of solid revenue but weak earnings execution.

Demand mix is improving, with AI-linked therapeutics taking a larger role

After a quarter that showed both better demand and better gross margin, the more important question is what kind of demand Twist is getting.

Higher-value segments are leading the growth

The growth was not evenly spread. DNA Synthesis and Protein Solutions revenue rose 39%, while NGS Applications revenue increased 12%. That matters because the faster-growing synthesis and protein work is where Twist's scale and repeat customer usage should matter most. More production-heavy and iteration-heavy demand is generally a better input for future profitability than one-off sequencing demand.

Twist also said demand was broad-based across therapeutics, diagnostics, academic and government customers, and international markets, while AI-enabled drug discovery and therapeutics were highlighted as major growth drivers. That points to a customer mix that may be becoming more valuable, not just larger.

Why AI-linked demand matters more than generic synthetic biology demand

Management said demand is tied to customers repeatedly using AI models in therapeutic design and expressed confidence in at least triple-digit order growth in both fiscal 2026 and fiscal 2027. If that demand is driven by iterative therapeutic workflows, it can create stickier usage and more synthesis spend across drug discovery programs.

The company also said early-access customers ordered more than 1,800 constructs for its Complex Genes offering. That does not prove monetization at scale yet, but it does suggest Twist is trying to move deeper into higher-value development workflows rather than selling only standard gene products.

What would validate the thesis

Bulls can argue this is the mix shift Twist needed: more therapeutic exposure, more repeat usage, and a product ladder that goes upmarket. Bears can argue that AI-linked demand is still early and that a small pipeline base can look volatile.

What to watch: - Whether synthesis and protein-related demand keeps outgrowing the rest of the business - Whether therapeutic and AI-linked use cases remain strong into Q4 - Whether Complex Genes keeps building from its early-access stage into broader commercial adoption

October needs to show that margin improvement can reach the bottom line

After the 7.7% premarket decline, the next test is not demand alone. It is whether Twist can turn improving gross margins into credible operating progress.

The October bar is specific

Management has reiterated Q4 FY26 Adj EBITDA breakeven, and the market will judge that claim against a quarter that already posted gross margin of 52.8%, up 120 basis points from the prior quarter. If gross-margin gains are translating into operating leverage, October should show cleaner progress toward profitability, not just another revenue beat.

The real debate: efficiency or execution

Bulls have a real data point: the sequential gross-margin improvement suggests the manufacturing engine is getting more efficient. Bears have the other side of the equation: adjusted earnings were still negative, so better gross profit has not yet become consistent bottom-line proof.

That is why October is pivotal. If Twist hits breakeven, the company can start to shake off the credibility gap. If it misses again, investors are likely to treat the profitability roadmap with the same caution they showed after Q3.

What would weaken the setup

Another revenue beat without an EBITDA improvement would reinforce the view that Twist still has an operating leverage problem. Similarly, if management does not show continued progress toward the $456 million-$457 million full-year range, the market may conclude the turnaround narrative is still ahead of the evidence.